Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Solid Biosciences鈥� 250-page 10-K can feel like decoding a genetic sequence. Trial protocols, vector design risks, and cash-burn tables are buried in dense language that makes it hard to answer one basic question: Is the next Duchenne milestone funded and on track?
That鈥檚 why Stock Titan pairs every document with AI-powered summaries that turn biotech jargon into clear insights. Need the Solid Biosciences quarterly earnings report 10-Q filing broken down line-by-line? Our engine highlights R&D spend shifts and runway projections in seconds. Curious about Solid Biosciences insider trading Form 4 transactions or the latest Solid Biosciences 8-K material events explained? AG真人官方-time EDGAR feeds alert you the moment they post, while plain-language notes flag anything that could move the share price.
Explore every form without searching page after page:
- 10-K & 10-Q 鈥� Cash runway and pipeline data, with the Solid Biosciences annual report 10-K simplified for quick reading.
- 8-K 鈥� Trial pauses, FDA feedback, partnerships, all filed under 鈥淪olid Biosciences earnings report filing analysis鈥�.
- Form 4 鈥� Track Solid Biosciences Form 4 insider transactions real-time and spot Solid Biosciences executive stock transactions Form 4 patterns.
- Proxy (DEF 14A) 鈥� See the full Solid Biosciences proxy statement executive compensation without hunting through attachments.
RA Capital and affiliated persons report owning 7,997,510 shares of Solid Biosciences (SLDB), representing approximately 9.9% of the outstanding common stock. The reported position includes 5,673,193 shares directly held by RA Capital Healthcare Fund, L.P., additional small direct holdings through related accounts and pre-funded warrants exercisable for up to 3,722,085 shares subject to a beneficial ownership blocker that prevents exercise above 9.99% ownership. Recent open-market purchases disclosed include 529,768 shares at a weighted-average of $4.49 and smaller buys at prices between $3.80 and $4.50 per share. RA Capital, Peter Kolchinsky and Rajeev Shah disclose shared voting and dispositive power over the reported shares and state delegations of voting/dispositive authority from certain funds.
Solid Biosciences Inc. Schedule 13G/A filing by Commodore Capital entities
Commodore Capital LP and Commodore Capital Master LP filed an amendment to Schedule 13G reporting zero shares beneficially owned of Solid Biosciences Inc. (CUSIP 83422E204), representing 0.0% of the class. The filing lists the issuers' principal office at 500 Rutherford Avenue, Charlestown, Massachusetts, and gives filing addresses for the two filers in New York and the Cayman Islands. Both filers state no sole or shared voting or dispositive power over any shares and certify the securities were not acquired to influence control of the issuer. The filing is signed by Michael Kramarz for both entities and references a Joint Filing Agreement as an exhibit.
Solid Biosciences Inc. (SLDB) reported expanded clinical progress and a strengthened balance sheet while continuing to record sizable operating losses. As of June 30, 2025 the company held $138.9 million in cash and cash equivalents and $129.2 million in available-for-sale securities, totaling $268.1 million of liquid resources (excluding $1.9 million restricted cash). Total assets were $308.3 million and total liabilities were $50.0 million, leaving stockholders' equity of $258.3 million.
The company posted net losses of $39.5 million and $78.8 million for the three and six months ended June 30, 2025, respectively, driven by research and development spending of $32.4 million and $63.3 million for the same periods. Clinical and regulatory milestones include SGT-003 dosing (15 participants dosed as of August 12, 2025) with reported initial biopsy expression of microdystrophin averaging 110%, SGT-212 IND clearance (Dec 2024), and SGT-501 IND clearance and Health Canada CTA approval (July 2025). The February 2025 offering generated approximately $188.0 million of net proceeds. The company expects its cash, cash equivalents and securities to fund operations into the first half of 2027.
Form 4 highlights: On 07/06/2025, Solid Biosciences Inc. (SLDB) director Ian F. Smith acquired 4,573 common shares through the mandatory conversion (Code M) of previously granted restricted stock units (RSUs). The RSUs, issued on 01/06/2025, vest in four equal quarterly tranches and convert to common stock on a 1-for-1 basis. Following the transaction, Smith now directly owns 122,119 common shares and retains 9,146 unvested RSUs. The RSUs will accelerate in full if the Executive Chair Agreement terminates early or upon a change in control of the company. No shares were sold, suggesting continued insider exposure to SLDB鈥檚 equity. The filing was signed on 07/08/2025.
Solid Biosciences (NASDAQ:SLDB) filed a routine Form 4 disclosing that director Georgia Keresty received a stock-option grant covering 77,500 shares on 06/12/2025 at an exercise price of $4.58 per share.
The option vests in full on the earlier of the one-year anniversary of the grant or immediately prior to the next annual shareholder meeting, and accelerates upon certain change-in-control events. It expires on 06/12/2035. No open-market purchases or sales of common stock were reported, and Keresty鈥檚 beneficial ownership now reflects only the newly granted option, held directly.
FAQ
What is the current stock price of Solid Bioscience (SLDB)?
What is the market cap of Solid Bioscience (SLDB)?
